Minerva: MIN-117 Meets Primary And Secondary Endpoints In Phase IIa Trial

(RTTNews) - Minerva Neurosciences, Inc. (NERV) reported positive top line results from a Phase IIa clinical trial in major depressive disorder with MIN-117, an antidepressant drug candidate. The company said the results demonstrated dose-dependent superiority of MIN-117 over placebo.

In the study, MIN-117 demonstrated a favorable tolerability profile, and the incidence and types of side effects did not differ significantly between the MIN-117 group and the placebo group. No unexpected adverse events were reported.

"We believe these results show a meaningful clinical benefit and support further development of MIN-117," said Remy Luthringer, president and CEO of Minerva.